Klotho Neurosciences, INC 10-Q quarterly reports

Greenland Mines Ltd. reports a strategic pivot to mining following the acquisition of the Skaergaard Project, while maintaining biotech operations and addressing going concern risks.

Klotho Neurosciences, Inc. reported a significant net loss for Q3 2025 and the nine months ended September 30, 2025, while substantially increasing cash reserves through financing activities, but faces a 'going concern' warning and Nasdaq compliance issues.

Klotho Neurosciences, a pre-revenue biotech, reported significantly increased losses for Q2 2025 but bolstered its cash position through recent capital raises and achieved Orphan Drug Designation for its ALS gene therapy.

Klotho Neurosciences' Q1 2025 results reveal a widened net loss and highlight substantial doubt about the company's ability to continue as a going concern without additional funding.

Klotho Neurosciences, Inc. reports a significant increase in net loss for the third quarter of 2024, primarily due to increased share-based compensation and expenses related to its recent business combination.

Anew Medical, Inc. reports its financial results for the quarter ended June 30, 2024, following its recent merger, highlighting increased operating expenses and a net loss, while also detailing its current assets, liabilities, and ongoing development of its licensed platforms.

Redwoods Acquisition Corp. reported a net loss of $123,223 for the quarter ended March 31, 2024, while continuing efforts to finalize its business combination with ANEW Medical, Inc.